ALK‐positive non–small cell lung cancer: Mechanisms of resistance and emerging treatment options

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|16|2392-2402

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.16, 2014-08, pp. : 2392-2402

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drug‐induced reduction in estimated glomerular filtration rate in patients with ALK‐positive non‐small cell lung cancer treated with the ALK inhibitor crizotinib

By  

CANCER, Vol. 120, Iss. 5, 2014-03 ,pp. : 664-674

John Wiley & Sons Inc

Access to resources Recommend Favorite

Experience in Integrating ALK Testing and Crizotinib into the Routine Treatment of Patients with Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 36, Iss. 6, 2013-04 ,pp. : 342-347

Karger

Access to resources Recommend Favorite

Phenotypic variation of an ALK‐positive large‐cell neuroendocrine lung carcinoma with carcinoid morphology during treatment with ALK inhibitors

By  

HISTOPATHOLOGY, Vol. 72, Iss. 4, 2018-03 ,pp. : 707-710

John Wiley & Sons Inc

Access to resources Recommend Favorite

Native and rearranged ALK copy number and rearranged cell count in non–small cell lung cancer

By  

CANCER, Vol. 119, Iss. 22, 2013-11 ,pp. : 3968-3975

John Wiley & Sons Inc

Access to resources Recommend Favorite

EML4-ALK Rearrangement and Its Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 83, Iss. 5, 2012-09 ,pp. : 248-256

Karger

Access to resources Recommend Favorite